Sean Murphy Acquires 15,000 Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) insider Sean Murphy acquired 15,000 shares of the company’s stock in a transaction dated Monday, January 27th. The shares were purchased at an average cost of $5.31 per share, with a total value of $79,650.00. Following the acquisition, the insider now owns 182,732 shares of the company’s stock, valued at approximately $970,306.92. This represents a 8.94 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink.

TriSalus Life Sciences Price Performance

Shares of TriSalus Life Sciences stock traded down $0.04 during trading on Wednesday, hitting $4.93. 16,469 shares of the company were exchanged, compared to its average volume of 23,643. The firm has a market capitalization of $150.32 million, a P/E ratio of -1.98 and a beta of 0.51. The firm’s fifty day moving average price is $4.55 and its 200 day moving average price is $4.75. TriSalus Life Sciences, Inc. has a 1-year low of $3.50 and a 1-year high of $10.42.

Institutional Investors Weigh In On TriSalus Life Sciences

Large investors have recently bought and sold shares of the company. Walleye Capital LLC bought a new stake in shares of TriSalus Life Sciences in the 3rd quarter valued at $66,000. Virtu Financial LLC acquired a new position in TriSalus Life Sciences in the third quarter valued at about $92,000. Vestcor Inc bought a new stake in shares of TriSalus Life Sciences in the third quarter worth about $108,000. MSD Partners L.P. acquired a new stake in shares of TriSalus Life Sciences during the third quarter worth about $184,000. Finally, Geode Capital Management LLC lifted its holdings in shares of TriSalus Life Sciences by 45.4% during the 3rd quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock valued at $924,000 after purchasing an additional 62,542 shares in the last quarter. Institutional investors own 2.58% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. Canaccord Genuity Group cut their price objective on TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Northland Capmk upgraded shares of TriSalus Life Sciences to a “strong-buy” rating in a research report on Friday, October 25th. Northland Securities assumed coverage on shares of TriSalus Life Sciences in a report on Friday, October 25th. They set an “outperform” rating and a $12.50 price objective on the stock. Roth Capital raised shares of TriSalus Life Sciences to a “strong-buy” rating in a research note on Monday, November 11th. Finally, Roth Mkm reissued a “buy” rating and set a $11.00 price target on shares of TriSalus Life Sciences in a research note on Friday, January 24th. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, TriSalus Life Sciences has a consensus rating of “Buy” and a consensus price target of $11.79.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.